Brought to you by 
AstraZeneca buys Novexel for $430mm up front
Dec 2009
Executive Summary
AstraZeneca will pay $350mm in cash to acquire privately held Novexel (antibiotics). It will also transfer to shareholders an amount equal to Novexel's cash balance when the deal closes (about $80mm), and could pay up to an additional $75mm in development-based earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Acquisition of Private Biotech
- Includes Earnout
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca buys Novexel for $430mm up front
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice